Abstract: Described are compositions and methods for treating liver disease, e.g., acute liver disease, using bone marrow-derived stem cells and bone marrow-derived stem cell conditioned media.

Abstract: A propulsion system comprising independent rotor sub-systems producing a thrust force of a desired magnitude in any desired radial direction from the center of the propulsion system, driven from a single driveshaft that may be fixed in its position in the vehicle. When the propulsion system is fitted, for example, to a single-main-rotor helicopter in place of the convention anti-torque tail rotor, the helicopter is thereby equipped with a propulsion system that can produce yaw, pitch, the anti-torque lateral thrust for stability in hover, aft thrust or drag as well as the direct forward thrust that will enable the helicopter to fly at higher speeds. The propulsion system may also be applied in other aeronautical systems as well as to marine and industrial systems to impart energy into a fluid and thereby induce movement in that fluid.

Abstract: Described are compositions and methods for treating liver disease, e.g., acute liver disease, using bone marrow-derived stem cells and bone marrow-derived stem cell conditioned media.

Abstract: A propulsion system comprising independent rotor sub-systems producing a thrust force of a desired magnitude in any desired radial direction from the centre of the propulsion system, driven from a single driveshaft that may be fixed in its position in the vehicle. When the propulsion system is fitted, for example, to a single-main-rotor helicopter in place of the convention anti-torque tail rotor, the helicopter is thereby equipped with a propulsion system that can produce yaw, pitch, the anti-torque lateral thrust for stability in hover, aft thrust or drag as well as the direct forward thrust that will enable the helicopter to fly at higher speeds. The propulsion system may also be applied in other aeronautical systems as well as to marine and industrial systems to impart energy into a fluid and thereby induce movement in that fluid.

Abstract: The present invention provides particular anti-inflammatory factors, compositions containing them, methods of making, identifying, and/or characterizing them, and methods of using them. In some embodiments, provided factors are expressed by human bone marrow stromal cells (MSC). In some embodiments, provided factors are characterized by an ability, when contacted with mammalian leukocytes in culture, to alter production of at least one inflammatory or anti-inflammatory agent by the mammalian leukocytes. In some embodiments, provided factors include GALNT1 polypeptides, LGALS3BP polypeptides, MFAP5 polypeptides, PENK polypeptides and/or HAPLN1 polypeptides. In some embodiments, provided factors are useful in the inhibition of inflammatory agents, in the promotion of anti-inflammatory agents, and/or for the treatment of subjects suffering from or susceptible to a disease, disorder or condition characterized by inflammation.

Abstract: The invention provides compositions and methods for modulating disease using hematopoietic stromal progenitor cells derived from hematopoietic tissues. The invention further provides methods for isolating, storing and culturing hematopoietic stromal progenitor cells.

Abstract: Provided are certain chemical entities, pharmaceutical compositions, and methods of treatment of a member of the flaviviradae family of viruses such as hepacivirus (Hepatitis C or HCV).

Abstract: The invention provides compositions and methods for modulating immune responses using mesenchymal stem cells. The invention further provides methods for inducing tolerance to self antigens using mesenchymal stem cells.

Abstract: Provided are certain chemical entities, pharmaceutical compositions, and methods of treatment of a member of the flaviviradae family of viruses such as hepacivirus (Hepatitis C or HCV).

Abstract: Common authentication and authorization (AA) between networks having disparate access technologies may enable a seamless user transition between the networks. A set of AA credentials from a user attempting to gain access to one of the networks may be received, and a subscriber database of another of the networks may be used to verify the set of AA credentials. A communication protocol common to the networks may be used. Additionally, the user may employ a single set of authentication and authorization (AA) credentials, usable over multiple communication protocol layers. Further, a user may perform a single authentication and authorization (AA) operation when roaming across two or more networks by gathering user's key material during an AA challenge and reply session at a data link layer. The gathered material may be used for an AA challenge at an upper network layer or another network as the user transitions between networks.

Abstract: Provided are certain chemical entities, pharmaceutical compositions, and methods of treatment of a member of the flaviviradae family of viruses such as hepacivirus (Hepatitis C or HCV).

Abstract: A mobile station is located and paged for a circuit-switched connection in a GSM system which supports data packet switching (GPRS) services. A table held by the SGSN is provided for locating a mobile station where the mobile has moved from the Routing Area in which it was last located to a cell within the same Location Area which does not support GPRS services. The GSM system comprises a plurality of base station controllers (BSS) serving cells in a Location Area (LA), a circuit-switch control (MSC/VLR) for establishing circuit-switched connections to mobile stations within the Location Area, and a packet control (SGSN) for establishing data packet-switching with mobile stations within one or more Routing Areas (RA) within the Location Area.

Abstract: Disclosed and claimed are compositions and methods for therapy and/or prevention of restenosis and/or atherosclerosis. The compositions can include an agent for inhibiting VEGF and an agent for including vessel maturation; for instance, the soluble VEGF receptor and ang-1. Embodiments can include kits.

Abstract: A therapeutic composition is provided that comprises a cell-free conditioned medium containing mixed secretion products of isolated angiogenic progenitor cells obtained from bone marrow, peripheral blood, or adipose tissue. The composition may additionally contain angiogenesis-promoting proteins obtained by transfecting the progenitors cells in culture with an angiogenesis promoting transgene. The composition is useful to promote angiogenesis when introduced into or adjacent to an ischemic site in a patient, such as in myocardium or peripheral limb. Methods are also provided for utilizing such cell-free conditioned medium to deliver angiogenesis-promoting proteins to a patient. The cell-free conditioned medium can also be injected into the blood stream for delivery to the ischemic tissue. The cells can derive from either an autologous or allogenic source and can be lyophilized or frozen for storage.

Abstract: Methods are provided for promoting formation of collateral blood supply at an ischemic site in tissue by culturing early attaching cells derived from growth of bone marrow aspirate in vitro, collecting early attaching cells produced by the bone marrow culture and injecting conditioned medium produced by culture of the early attaching cells into an ischemic site in heart or limb. The preferred early attaching cells for use in the invention methods are marrow-derived stromal cells. Any donor's bone marrow can be used in preparation of the conditioned medium. Optionally, the early attaching cells can be transfected with an angiogenesis promoting transgene encoding hypoxia inducing factor 1 alpha, a fibroblast growth factor and/or a nitric oxide synthase. Conditioned media containing angiogenic cytokines produced such cells are also provided for injection into tissue, such as heart or peripheral limb muscle, requiring formation of collateral blood supply.

Abstract: A stent includes a lattice defining a substantially cylindrical configuration having a proximal end portion and a distal end portion, and a middle portion between the proximal end and the distal end. The lattice being moveable from a crimped state to an expanded state, and a plurality of adjacent hoops. Each hoop has a plurality of adjacent loops. Additionally, the stent further includes a plurality of bridges connecting adjacent hoops and a plurality of extensions on the lattice. Each of the hoops and bridges define a cell. The proximal end portion and the distal end portion of the lattice have at least one cell respectively and the middle portion of the lattice has at least one cell. The plurality of extensions are on the middle portion of the lattice. The plurality of extensions are cantilevered projections from the bridges and/or hoops of the lattice.

Abstract: A method for treating a bifurcated vessel, wherein the bifurcated vessel has a main vessel and a side branch vessel extending from the main vessel. The method includes the steps of: identifying a site in the main vessel and placing a stent at the site in the main vessel. The stent includes a lattice defining a substantially cylindrical configuration having a proximal end portion and a distal end portion, and a middle portion between the proximal end portion and the distal end portion. The lattice is movable from a crimped state to an expanded state. The lattice has a plurality of adjacent hoops. Each hoop has a plurality of adjacent loops, a plurality of bridges connecting adjacent hoops, and a plurality of extensions on at least some portions of the lattice. Each of the hoops and bridges define a cell. The proximal end portion and the distal end portion of the lattice have at least one cell respectively and the middle portion of the lattice has at least one cell.

Abstract: A method of generating a unified billing statement common to at least two independent networks is described, where accounting records of a user are collected from at least two networks and a single billing statement encompassing the two networks is generated for the user based on the accounting records. The accounting records may include Call Data Records (CDRs) in a UMTS, Usage Data Records (UDRs) in a cdma2000 system and accounting records of a wireless local area network (WLAN), for example. The accounting records may include user attribute information common to each of the networks. This common user attribute information may be used to generate common billing records which are then used to generate the single, unified billing.

Abstract: Common authentication and authorization (AA) between networks having disparate access technologies may enable a seamless user transition between the networks. A set of AA credentials from a user attempting to gain access to one of the networks may be received, and a subscriber database of another of the networks may be used to verify the set of AA credentials. A communication protocol common to the networks may be used. Additionally, the user may employ a single set of authentication and authorization (AA) credentials, usable over multiple communication protocol layers. Further, a user may perform a single authentication and authorization (AA) operation when roaming across two or more networks by gathering user's key material during an AA challenge and reply session at a data link layer. The gathered material may be used for an AA challenge at an upper network layer or another network as the user transitions between networks.

Abstract: Disclosed and claimed are compositions and methods for therapy and/or prevention of restenosis and/or atherosclerosis. The compositions can include an agent for inhibiting VEGF and an agent for inducing vessel maturation; for instance, the soluble VEGF receptor and ang-1. Embodiments can include kits.